Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more

Recent & Breaking News (NDAQ:INSM)

Get A Stock Report On Disney, The Goldman Sachs Group, Hewlett Packard Enterprise Company, Insmed inc., Trivago, Or Any Stock You Choose.

PR Newswire September 6, 2017

25 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  September 6, 2017

Insmed Announces Proposed Public Offering of Common Stock

GlobeNewswire September 5, 2017

Mid-Day Market Update: Crude Oil Up Over 3%; Cellectis Shares Plummet

Benzinga.com  September 5, 2017

Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)

GlobeNewswire September 5, 2017

Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire August 3, 2017

Investor Network: Insmed Incorporated to Host Earnings Call

Accesswire August 3, 2017

Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017

GlobeNewswire July 27, 2017

Insmed to Host Analyst and Investor Day on July 19, 2017

GlobeNewswire July 12, 2017

Insmed to Present at the JMP Securities Life Sciences Conference

GlobeNewswire June 13, 2017

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire June 8, 2017

Insmed Announces Key Additions to its Executive Management Team

GlobeNewswire May 15, 2017

Insmed Reports First Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire May 3, 2017

Investor Network: Insmed Incorporated to Host Earnings Call

Accesswire May 3, 2017

Insmed to Present at the Deutsche Bank 42nd Annual Health Care Conference

GlobeNewswire April 27, 2017

Insmed to Host First Quarter 2017 Financial Results Conference Call on Wednesday, May 3, 2017

GlobeNewswire April 26, 2017

Insmed to Present at the Cowen and Company 37th Annual Health Care Conference

GlobeNewswire February 28, 2017

Insmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update

GlobeNewswire February 23, 2017

Insmed to Host Fourth Quarter and Year-end 2016 Financial Results Conference Call on Thursday, February 23, 2017

GlobeNewswire February 16, 2017

Insmed Inc. Extends ARIKAYCE Intellectual Property Protection with Issuance of New U.S. Patent

GlobeNewswire February 14, 2017
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested